FDA approves Celltrion, Teva’s Rituxan biosimilar, but with a narrow label

FDA approves Celltrion, Teva’s Rituxan biosimilar, but with a narrow label

The agency approved Truxima for three lymphoma indications, whereas European regulators approved it last year for all the same indications as the reference product, Roche’s Rituxan.

Source: https://ift.tt/2AG2LPB